Cardiol Therapeutics: B. Riley Sees 450% Upside as Phase 3 MAVERIC Trial Nears Completion
B. Riley initiates Cardiol Therapeutics at Buy with an $11 target, citing a de-risked Phase 3 MAVERIC trial and strong cash runway.
B. Riley initiates Cardiol Therapeutics at Buy with an $11 target, citing a de-risked Phase 3 MAVERIC trial and strong cash runway.
Agomab trades at a deep discount to Sarepta and Abivax. Piper Sandler starts at Overweight with $60 PT.
BofA and Cantor Fitzgerald initiate coverage on Apnimed with Buy and Overweight ratings for Oxnimbi, its oral therapy for obstructive sleep apnea.
HARMONi Phase 3 results in The Lancet Oncology show ivonescimab + chemo cuts progression risk nearly in half for post-TKI EGFR-mutated NSCLC.
Oppenheimer raises Capricor to Outperform on clearer path for deramiocel. $54 target, PDUFA Nov 22 after upper-limb focus.
Wolfe Research upgrades Moderna to Peer Perform following Phase 3 intismeran success and a potential $9.2 billion peak sales outlook.